Those who continued the medication maintained or continued to lose weight, while those who stopped regained much of the weight lost, underscoring the need for long-term therapy.23 Longer-term outcomes were assessed in STEP 5, which extended treatment to 104 weeks and demonstrated sustained weight loss of approximately 15%.24 In East Asian populations, STEP 6 showed similar results, with participants achieving an average 12% to 13% weight loss over 68 weeks.25 STEP 7, a 44-week trial including participants from China, Hong Kong, Brazil, and South Korea, found that those on semaglutide lost an average of 12.1% of their body weight compared with 3.6% with placebo.26 Lastly, STEP 8 compared semaglutide with liraglutide and showed greater efficacy with semaglutide (15.8% vs 6.4% weight loss), as well as better tolerability and more convenient weekly dosing.27 Taken together, the STEP trials show that semaglutide consistently results in clinically meaningful weight loss across various populations and treatment conditions

GH and testosterone have well-documented additive effects on body composition testosterone drives muscle protein synthesis through androgen receptor activation, while GH promotes lipolysis, collagen synthesis, and tissue repair through separate pathways
Long-term potentiation of neuron-glia synapses mediated by Ca2+permeable AMPA receptors
As a result, some individuals taking these medications may experience symptoms similar to gastroparesis, such as nausea, vomiting, and delayed stomach emptying
For questions about specific products, substances, and methods, contact USADAs Drug Reference Line at [email protected] or call (719) 785-2000, option 2.